What Researchers Did
Researchers conducted a systematic review to analyze the potential role of hyperbaric oxygen therapy (HBOT) in improving chronic fatigue, cognitive impairments, and neurological disorders associated with Long COVID.
What They Found
The review identified 21 studies published between January 2021 and October 2025, comprising one case report, ten randomized controlled trials, eight systematic reviews, and three studies on molecular mechanisms. These studies suggested that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms, and cardiopulmonary function in Long COVID patients.
What This Means for Canadian Patients
Canadian patients experiencing persistent Long COVID symptoms like fatigue or cognitive issues might find hyperbaric oxygen therapy to be a potential treatment option. Consulting with a healthcare provider about this therapy could help manage their lingering symptoms.
Canadian Relevance
This systematic review did not include any specific Canadian studies or data, therefore, there is no direct Canadian relevance.
Study Limitations
A limitation of this systematic review is the potential heterogeneity and varying quality of the 21 included studies, which comprised diverse methodologies.